Transplantation of human umbilical cord blood mononuclear cells for treatment of myocardial infarction with heart failure

doi:10.3969/j.issn.2095-4344.2014.50.012

Abstract

Abstract:

BACKGROUND: Increasing basic researches have confirmed that human umbilical cord blood stem cells is safe and effective to treat acute myocardial infarction complicated by heart failure, but this method is not yet available for clinical use.
OBJECTIVE: To observe the long-term effect of human umbilical cord blood mononuclear cell transplantation in the treatment of myocardial infarction combined with heart failure.
METHODS: Twenty-five patients with myocardial infarction and heart failure admitted in the Department of Cardiology, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, from January 2009 to June 2011 were randomly assigned to receive intracoronary transplantation of human umbilical cord blood mononuclear cells in addition to conventional therapy (transplantation group, n=12) or standard therapy (control group, n=13). All patients underwent standardized drug therapy, and coronary angiography and percutaneous coronary intervention were performed at acute phase. Improvement in heart function, left ventricular ejection fraction, left ventricular end-systolic volume and left ventricular end-diastolic volume at baseline and 12, 24 months after treatment were monitored.
RESULTS AND CONCLUSION: The left ventricular ejection fraction, left ventricular end-systolic volume and left ventricular end-diastolic volume were significantly improved 12, 24 months after human umbilical cord blood stem cell transplantation compared to baseline (P < 0.05), while these parameters remained unchanged in the control group (P > 0.05). Compared with the control group, the left ventricular ejection fraction was increased significantly, and the left ventricular end-systolic volume and left ventricular end-diastolic volume were reduced significantly in the transplantation group. During the follow-up, no side effects were observed. These findings indicate that human umbilical cord blood mononuclear cell transplantation leads to significant and longstanding improvements in left ventricular performance of patients with myocardial infarction and heart failure.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: cord blood stem cell transplantation, myocardial infarction, heart failure, treatment outcome

CLC Number:

R394.2

Yu Le, Zhang Ming. Transplantation of human umbilical cord blood mononuclear cells for treatment of myocardial infarction with heart failure[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(50): 8103-8107.

Figures/Tables 2

References

[1] Pfister O, Della Verde G, Liao R, et al. Regenerative therapy for cardiovascular disease.Transl Res. 2014;163(4): 307-320.
[2] Sánchez LA, Guerrero-Beltrán CE, Cordero-Reyes AM, et al. Use of stem cells in heart failure treatment: where we stand and where we are going. Methodist Debakey Cardiovasc J. 2013;9(4):195-200.
[3] Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. 2013;113(6):810-834.
[4] Boyle AJ, Schulman SP, Hare JM, et al. Is stem cell therapy ready for patients? Stem cell therapy for cardiac repair. Ready for the next step. Circulation. 2006;114(4):339-352.
[5] Kajstura J, Urbanek K, Perl S, et al. Cardiomyogenesis in the adult human heart.Circ Res. 2010;107(2):305-315.
[6] Schächinger V, Erbs S, Elsässer A, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006;27(23):2775-2783.
[7] Assmus B, Rolf A, Erbs S, et al. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail. 2010;3(1):89-96.
[8] Sadat K, Ather S, Aljaroudi W, et al. The effect of bone marrow mononuclear stem cell therapy on left ventricular function and myocardial perfusion. J Nucl Cardiol. 2014; 21(2):351-367.
[9] Yousef M, Schannwell CM, Köstering M, et al. The BALANCE Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J Am Coll Cardiol. 2009;53(24):2262-2269.
[10] Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J. 2009;30(24):2978-2984.
[11] Mielewczik M, Cole GD, Nowbar AN, et al. The C-CURE Randomized Clinical Trial (Cardiopoietic stem Cell therapy in heart failURE). J Am Coll Cardiol. 2013;62(25):2453.
[12] Furfaro EM, Gaballa MA. Do adult stem cells ameliorate the damaged myocardium? Human cord blood as a potential source of stem cells. Curr Vasc Pharmacol. 2007;5(1): 27-44.
[13] Jaing TH, Hsia SH, Chiu CH, et al. Successful unrelated cord blood transplantation in a girl with malignant infantile osteopetrosis. Chin Med J (Engl). 2008;121(13):1245-1246.
[14] Martins AA, Paiva A, Morgado JM, et al. Quantification and immunophenotypic characterization of bone marrow and umbilical cord blood mesenchymal stem cells by multicolor flow cytometry. Transplant Proc. 2009;41(3):943-946.
[15] Poliachenko IuV, Habriielian AV, Domans'ky? TM, et al. Effects of the umbilical blood stem cells in experimental injury of myocardium. Klin Khir. 2013;(7):56-60.
[16] Bewley S, Mercer J. Using umbilical cord blood stem cells for myocardial infarction and stroke is ethically challenging. Clin Med. 2010;10(1):97; author reply 97-98.
[17] Greco N, Laughlin MJ. Umbilical cord blood stem cells for myocardial repair and regeneration. Methods Mol Biol. 2010;660:29-52.
[18] Rabald S, Marx G, Mix B, et al. Cord blood cell therapy alters LV remodeling and cytokine expression but does not improve heart function after myocardial infarction in rats. Cell Physiol Biochem. 2008;21(5-6):395-408.
[19] Leor J, Guetta E, Feinberg MS, et al. Human umbilical cord blood-derived CD133+ cells enhance function and repair of the infarcted myocardium. Stem Cells. 2006;24(3):772-780.
[20] Henning RJ, Shariff M, Eadula U, et al. Human cord blood mononuclear cells decrease cytokines and inflammatory cells in acute myocardial infarction. Stem Cells Dev. 2008; 17(6):1207-1219.
[21] Zhang M, Yu L. Umbilical cord blood mononuclear cell transplantation is safe for treatment of coronary heart disease with heart failure. Zhongguo Zuzhi Gongcheng Yanjiu. 2013;17(49):8557-8562.
[22] Hirata Y, Sata M, Motomura N,et al.Human umbilical cord blood cells improve cardiac function after myocardial infarction. Biochem Biophys Res Commun. 2005; 327(2): 609-614.